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Available online 29 April 2016Background: Factors causing resistance to renal denervation (RDN) for treatment of arterial hypertension are not
known. In the current study, we sought to determine mechanisms involved in responsiveness to renal denerva-
tion therapy in patients with difﬁcult-to-control and resistant hypertension.
Methods and results: We evaluated the differential CpG methylation of genes in blood samples isolated from
patients of a recently described cohort of responders or non-responders to renal denervation using microarray
technique and measured protein levels of identiﬁed downstream effectors in blood samples of these patients
by ELISA.
Our analysis revealed up to 6103 methylation sites differing signiﬁcantly between non-responders and re-
sponders to renal denervation therapy. Software based analysis showed several of these loci to be relevant for ar-
terial hypertension and sympathetic nervous activity. Particularly, genes involved in glutamate synthesis,
degradation and glutamate signaling pathways were differently methylated between both groups. For instance,
genes for glutamate dehydrogenase 1 and 2 central to glutamate metabolism, genes for ionotropic (AMPA,
NMDA) andmetabotropic glutamate receptors as well as glutamate transporters revealed signiﬁcant differences
inmethylation correlatingwith responsiveness to RDN. To underline their potential relevance for responsiveness
to RDN, wemeasured plasma protein levels of norepinephrine, a downstream effector of the glutamate receptor
pathway, which were signiﬁcantly lower in non-responders to RDN.
Conclusions: The present study describes novel molecular targets potentially contributing to reduction of blood
pressure after RDN in some patients. Identifying patients with a high responsiveness to RDN could contribute
to an individualized therapy in drug resistant hypertension.
© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Renal denervation therapy1. Introduction
Catheter-based renal sympathetic denervation (RDN) is a novel
treatment option in patients with resistant hypertension [1]. However,
RDN is an invasive procedure with the inherent risks of side effects.
The net clinical beneﬁt of this procedure is subject of ongoing clinical
trials [2], and clear determinants to predict beneﬁcial outcome of this
intervention are warranted.itoring; AF, atrialﬁbrillation; BP,
omerular ﬁltration rate; NE,
lmonal vein isolation.
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land Ltd. This is an open access articlDuring RDN, sympathetic outﬂow to the kidney is reduced by
inﬂicting damage to the renal peri-vascular nervous system [3]. Since
the ﬁrst description of interventional renal denervation, several
experimental and clinical studies suggested a beneﬁcial effect on arterial
hypertension [4–6]. RDN was also suggested to have effects on patho-
physiological settings other than arterial hypertension such as ventricular
arrhythmias, glucose metabolism or insulin sensitivity [7,8]. While the
underlying mechanisms are not entirely characterized, in the setting of
catecholamine dependent ventricular tachycardia, modulation of
cardio-cardiac reﬂexes of sympathetic origin may account for the
observed effects [9–12]. Now, experimental and clinical research tries to
deﬁne indicators, which can predict RDN success, and clinical markers
to identify patients responding to the procedure.
Although arterial hypertension is amultifactorial disease, dysregula-
tion of sympathetic/parasympathetic activity is a central mechanism
of its pathophysiology. Accordingly, sympathetic nerve activity is
considered a major contributor to the pathophysiology of arteriale under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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changes in signaling tailored by epigenetic changes in expression of
molecules associated with the sympathetic signaling transduction
[14]. For example in patients suffering from postural tachycardia syn-
drome, it was demonstrated that expression of the norepinephrine
transporter is inhibited by suppressive histone-methylation [15].
These pathophysiological considerations render the sympathetic regu-
latory system a potential candidate to understandmechanisms of resis-
tance to blood pressure regulation. Recently, we described a novel
approach to identify patients as responders or non-responders to RDN
by measuring baroreﬂex sensitivity (BRS) obtained from non-invasive
recordings as surrogate measure for underlying sympathetic tone [16].
Wewere able to demonstrate that impairedBRSwas a strong and signif-
icant predictor of response to RDN [16]. Epigenetic regulation is
discussed as one of the emerging mechanisms affecting arterial hyper-
tension [17]. To uncover possible targets, which affect responsiveness
to RDN, we performed microarray analysis of responders and non-
responders in our BRS patient collective and determined differential
methylation possibly resulting in decreased DNA transcription.2. Materials and methods
2.1. Ethics
Patients' samples were obtained after patients gave written and in-
formed consent. The study was approved by the local ethics committee
and conforms with the ethical principles outlined in the Declaration of
Helsinki.2.2. Patients
The study includes 5 randomly selected responders as well as age-,
gender-, glomerular ﬁltration rate (GFR)-, treatment- and blood pres-
sure-matched non-responders of a previously described cohort with re-
sistant arterial hypertension undergoing RDN [16]. Brieﬂy, inclusion
criteria were deﬁned as follows: patients were 18 years or older, had
an ofﬁce based BP of ≥160 mm Hg, a mean systolic BP of ≥130 mm Hg
on ambulatory blood pressure monitoring (ABPM) were on at least 3
antihypertensive drugs, had a GFR of ≥45 ml/min−1/1.73 m−2 and no
known secondary cause of high BP except sleep apnea or chronic kidney
disease. Identically to our previous report [16], response to RDNwas de-
ﬁned as reduction of mean systolic arterial blood pressure of 10 mmHg
or greater 6 months after RDN.2.3. Sample collection
In patients undergoing RDN, blood was taken from the arterial fem-
oral access at the beginning of the procedure. Blood samples were then
immediately transferred to blood collection tubes containing EDTA
(Sarstedt, Nuembrecht, Germany). Blood samples for DNA analysis
were immediately frozen as a whole and stored at−80 °C. For isolation
of EDTA plasma, samples were spun down at room temperature at
1250 ×g for 10 min. Plasma samples were then collected and stored at
−80 °C.2.4. Norepinephrine (NE) enzyme linked immunosorbent assays (ELISA)
EDTA plasma samples were thawed on ice, resuspended and ana-
lyzed using a NE ELISA (Labor Diagnostika Nord, Nordhorn, Germany)
following the manufacturer's protocol. All samples were analyzed in
duplicate and measured on a microplate reader (Bio-Rad Laboratories,
Munich, Germany) at 450 nm. n = 5 samples were analyzed for re-
sponders and nonresponders.2.5. BRS-PRSA
Assessment of cardiac BRS was carried out as described before [16].
Brieﬂy, patients underwent simultaneous 30-min high-resolution
electrocardiographic recordings (1.6 kHz in orthogonal XYZ leads)
and noninvasive continuous arterial BP monitoring using a ﬁnger
hotoplethysmographic device (Finapres; TNO-TPD Biomedical Instru-
mentation, Amsterdam, the Netherlands). The recordings were analyzed
according to standardized conditions by an experienced technician
blinded to the clinical status of the patient. Cardiac BRS was assessed
from the series of RR intervals and systolic BP values by phase-rectiﬁed
signal averaging (PRSA). For BRS-PRSA, increases of systolic BP (BP) are
identiﬁed within the BP time series. Subsequently, segments of RR inter-
vals around BP are identiﬁed and averaged. The resulting bivariate PRSA
signal shows RR oscillations related to increases of systolic BP, whereas
heart rate variability due to other causes is eliminated by the averaging
process.
2.6. Methylation array
Total DNA was isolated from frozen 2.8 ml EDTA blood samples
(n = 5) for responders and nonresponders respectively using the
QIAamp DNA Mini Kit (QIAgen, Hilden, Germany) according to the
manufacturer's protocol.
500 ng of total DNA were bisulﬁte converted for methylation
analysis according to the manufacturer's protocol using the EZ DNA
Methylation Kit (Zymo Research, Irvine CA, USA). Bisulﬁte converted
DNA was then applied to Inﬁnium Human Methylation450 BeadChip
(Illumina, San Diego CA, USA) and analyzed using an Illumina iScan
microarray scanner (Illumina, San Diego CA, USA) according to the
manufacturer's protocol. Genes differing in methylation with high
signiﬁcance were further analyzed for association with regulatory
pathways, networks and disease. Data analysis was performed
using GenomeStudio software (Illumina, San Diego CA, USA) and
QIAGEN's Ingenuity® Pathway Analysis (IPA®, QIAGEN Redwood
City, www.qiagen.com/ingenuity). The pathways shown were gen-
erated through the use of QIAGEN's Ingenuity Pathway Analysis
(IPA®,QIAGEN Redwood City, www.qiagen.com/ingenuity). Methyl-
ation analysis was performed at the Department of Medical Genetics,
Microarray Facility, Tuebingen, Germany.
2.7. Statistical analysis
Preliminary statistical analysis of methylation data was carried out
in the programming environment “R” using the packages “lumi” and
“methylumi”. Resulting β-values were normalized and converted to
M-values using logit-transformation. M-values were analyzed in “R”
using the “limma” package. For methylation array statistical analysis,
genes were considered signiﬁcantly different between both groups (re-
sponder vs. nonresponders), if β-values of at least an absolute 10%were
observed. Methylation sites meeting this requirement and showing an
uncorrected p-value of p ≤ 0.05 were considered for pathway analysis.
For ELISA and BRS-PRSA values, statistical analysis was performed
with SPSS (version 22, IBM Deutschland GmbH, Ehningen, Germany).
Concentrations obtained in the ELISA-assay were compared using
Mann–Whitney U-test.
3. Results
The patients' characteristics of “responders or nonresponders to
RDN” are depicted in Table 1. There was no signiﬁcant difference re-
garding factors important for the pathogenesis of arterial hypertension
such as gender, body mass index or diabetes. Comparing patients
responding to RDN with nonresponders, we were able to identify a
large number of sites with differential CpG-methylation. Criteria for se-
lection of methylation sites for further analysis of genes are given in
Table 1
Base line characteristics.
Variable Responder
(n = 5)
Non-responder
(n = 5)
p-Value
Age 57 +/− 14 55 +/− 21 0.684
Female gender 3/5 (60%) 1/5 (20%) 0.524
Body mass index 33 +/− 5 29 +/− 4 0.721
Diabetes mellitus 2/5 (40%) 3/5 (60%) 1.000
# antihypertensive med. baseline 4.2 +/− 1.1 5.0 +/− 0.7 0.067
# antihypertensive med. 6 months 4.8 +/− 1.1 4.2 +/− 1.1 0.623
Systolic BP baseline (mm Hg) 161 +/− 11 149 +/− 17 0.664
Systolic BP 6 months (mm Hg) 135 +/− 6 145 +/− 12 0.198
Patient characteristics.
Table 2
Differential methylation between responders and non-responders to RDN.
Gene
symbol
Encoded protein/RNA β-Diff
ACE2 Angiotensin-converting enzyme 2 −0.114
ADRA1A Alpha-1A adrenergic receptor −0.199
ADRA2C Alpha-2C adrenergic receptor −0.120
AFF3 AF4/FMR2 family member 3 0.516
ALOX12 Arachidonate 12-lipoxygenase, 12S-type −0.369
ARHGEF10 Rho guanine nucleotide exchange factor 10 −0.103
ATP2B3 Plasma membrane calcium-transporting ATPase 3 −0.177
CA5B Carbonic anhydrase 5B, mitochondrial 0.138
CACNA1F Voltage-dependent L-type calcium channel subunit
alpha-1F
0.143
CBX7 Chromobox protein homolog 7 −0.193
CCDC81 Coiled-coil domain-containing protein 81 0.112
CELF4 CUGBP Elav-like family member 4 0.226
CHM Rab proteins geranylgeranyltransferase component A1 0.126
CYB5B Cytochrome b5 type B −0.120
DNAJB6 DnaJ homolog subfamily B member 6 −0.543
FANCB Fanconi anemia group B protein 0.165
FHL1 Four and a half LIM domain protein 1 0.136
GALNT18 Polypeptide N-acetylgalactosaminyltransferase 18 0.119
GPIHBP1 Glycosylphosphatidylinositol-anchored high density
lipoprotein-binding protein 1
−0.118
GYPC Glycophorin-C 0.135
HUWE1 E3 ubiquitin-protein ligase HUWE1 0.134
JARID2 Protein Jumonji −0.114
LINC00087 Long intergenic non-protein coding RNA 87 0.102
LMO3 LIM domain only protein 3 0.119
LONRF3 LON peptidase N-terminal domain and RING ﬁnger protein 3 0.132
MAOA Amine oxidase [ﬂavin-containing] A 0.143
MXRA5 Matrix-remodeling-associated protein 5 −0.160
NEGR1 Neuronal growth regulator 1 −0.318
NKRF NF-kappa-B-repressing factor 0.148
NMNAT3 Nicotinamide/nicotinic acid mononucleotide
adenylyltransferase 3
−0.309
NOTCH4 Neurogenic locus notch homolog protein 4 0.440
PDE11A Dual 3,5-cyclic-AMP and -GMP phosphodiesterase 11A −0.259
PDZD4 PDZ domain-containing protein 4 0.107
PIGA Phosphatidylinositol N-acetylglucosaminyltransferase
subunit A
0.110
PNMA3 Paraneoplastic antigen Ma3 0.283
PRRG1 Transmembrane gamma-carboxyglutamic acid protein 1 0.106
PTGFR Prostaglandin F2-alpha receptor 0.184
RAB1A Ras-related protein Rab-1A 0.225
RBFOX1 RNA binding protein fox-1 homolog 1 0.105
RBFOX3 RNA binding protein fox-1 homolog 3 −0.175
SCN4B Sodium channel subunit beta-4 0.248
SLC39A8 Zinc transporter ZIP8 0.203
SLC6A1 Sodium- and chloride-dependent GABA transporter 1 0.118
SLC6A2 Sodium-dependent noradrenaline transporter −0.147
SLC7A3 Cationic amino acid transporter 3 0.226
SLITRK4 SLIT and NTRK-like protein 4 0.142
SRPX Sushi repeat-containing protein SRPX 0.108
THBS2 Thrombospondin-2 −0.115
TIMP1 Metalloproteinase inhibitor 1 0.135
TMEM47 Transmembrane protein 47 0.254
TMSB15B Thymosin beta-15B 0.144
WDR27 WD repeat-containing protein 27 0.114
XPNPEP2 Xaa-Pro aminopeptidase 2 −0.132
ZDHHC15 Palmitoyltransferase ZDHHC15 0.133
ZNF614 Zinc ﬁnger protein 614 0.234
Genes showing differentialmethylation in responders vs nonresponders (p ≤ 0.05) and as-
sociated with hypertension according to software based analysis (p ≤ 0.05); ß-Diff =
methylation (responder)−methylation (nonresponder).
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groups with a minimum difference in methylation of at least 10% abso-
lute and conﬁdence interval p ≤ 0.05 were considered for software
based pathway analysis. Analysis of 6103 sites meeting these
predeﬁned criteria of signiﬁcance revealed a group of 56 differentially
methylated genes to be potentially associated with hypertension
(Table 2). Further analysis indicated a potential modiﬁcation of path-
ways linked to hypertension such as glutamate biosynthesis and degra-
dation (both p b 0.005) aswell as glutamate signaling (p b 0.05) (Fig. 1).
Interestingly, also parts of non-expected pathways such as genes in-
volved in antigen presentation or IL-4 signaling were differentially
methylated (Fig. 1). In glutamate signaling, the affected genes encode
both ionotropic and metabotropic glutamate receptors, located mainly
in the postsynaptic neuron (Fig. 2). Furthermore, we also identiﬁed glu-
tamate transporters and a calcium dependent kinase, mostly located in
the presynaptic neuron being differentially methylated between re-
sponders and non-responders to RDN (Fig. 2, Table 3). Genes involved
in glutamate biosynthesis and degradation can be classiﬁed as gluta-
mate dehydrogenases mediating both processes (Fig. 3, Table 3).
As these differential methylations may cause differences in sympa-
thetic function changes in NE plasma levels [18,19], we measured NE
levels in responders and nonresponders. Interestingly, we detected a
signiﬁcantly lower concentration of norepinephrine (Fig. 4A) in the
blood of patients not responding to RDN compared to responders
(p b 0.05). Moreover, plasma NE levels showed an inverse correlation
with BRS-PRSA signals (Pearson coefﬁcient r =−0.70, p ≤ 0.05, Fig. 4B).
4. Discussion
Patients suffering from arterial hypertension, which are beyond any
further promisingmedical treatment eventually will develop complica-
tions such as chronic cardiovascular disease, stroke or acute myocardial
infarction associated with high morbidity and mortality. Therefore,
novel alternative treatment options such as interventional renal dener-
vation are urgently needed to improve quality of life and clinical out-
come in these patients. In a recently described patient cohort, we
assessed responsiveness to renal denervation by cardiac BRS to select
optimal candidates for RDN and to identify patients, in which RDN
should be avoided [16]. This is of particular clinical relevance, as a recent
randomized trial showed no substantial beneﬁt for RDN over the sham
procedure [20].
Here, we characterized underlying mechanisms of “response or
resistance” to renal denervation using microarray chip technology.
For instance, we analyzed patients classiﬁed as “non-responders”
or “responders” to RDN based on their decrease in ABPMwith regard
to regulated pathways potentially affecting the sympathetic nervous
system.We i) identiﬁed pathways and a number of genes involved in
hypertension differentially methylated between responders and
non-responders to RDN, ii) observed that genes important for
neuronal glutamate signal transduction or glutamate biosynthesis/
degradation were differentially methylated in responders vs
nonresponders and iii) measured signiﬁcantly lower levels ofnorepinephrine, a central downstream effector of the glutamate re-
ceptor pathway, in blood samples of non-responders to RDN.
The sympathetic nervous system controls blood pressure through
glucosensitive, thermosensitive and barosensitive relays responsible
for the control of short and long-term blood pressure. These sensors
control norepinephrine release from organs such as the heart, kidneys
and from a subset of adrenal chromafﬁne cells, and as a consequence
vessel resistance by constriction of arterioles [21]. Moreover, they play
a role in renin secretion, sodium reabsorption in renal tubules and
Fig. 1. Association of differentially methylated genes with signaling pathways in responders vs nonresponders to RDN. Numbers at the end of bars indicate number of genes in the
underlying pathway, ﬁlled bars indicate percentage of differentially methylated genes; green color indicates lower methylation, red color stronger methylation in the responder group.
Statistical signiﬁcance (p b 0.05) and, thus, non-random association of genes to pathways is indicated by the yellow curve showing−log (p-value).
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pathophysiological considerations and the strong abundance of efferent
sympathetic nerves located around the kidney arteries, the approach of
RDN to treat patients with arterial hypertension resistant to regular
medical antihypertensive treatment was proposed. In clinical trials, it
was demonstrated that RDN can attenuate efferent renal sympathetic
activity, which was demonstrated by assessment of NE spillover(Symplicity HTN1) [6] or dampening of central sympathetic activity as
veriﬁed by effects on muscle sympathetic nerve activity and cardiac
BRS [6,23]. As we detected differing plasma NE levels, it is tempting to
speculate that this is one of the reasons, why responders are more sus-
ceptible to modulation of sympathetic drive by renal denervation ther-
apy than non-responders. In other words, in patients with lower NE
levels, the “target” for renal denervation therapy may be missing.
Fig. 2.Molecules involved in glutamate receptor signaling and their synaptic location. Icons in red color indicate strongermethylation for samples isolated from responders to RDN, genes
in green indicate lower methylation. CALM: calmodulin. GRIA = glutamate receptor, ionotropic AMPA. GRIK = glutamate receptor, ionotropic kainate. GRIN = glutamate receptor,
ionotropic NMDA. GRM8= glutamate receptor, metabotropic 8. SLC1A 6/7 = solute carrier family 1, member 6/7. SLC17 = solute carrier family 17.
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tension shown in Table 2 could indicate possible physiological differ-
ences between responders and non-responders resulting in different
RDN outcome. The gene ACE2 encoding the angiotensin I converting
enzyme 2, a homolog of ACE, showed increased methylation in the
non-responders group. ACE2 functions as a monocarboxypeptidase
with the primary function of degrading Ang II to Ang 1–7, which in
turn acts through its recepetor Mas changing the balance of the renin
angiotensin system from vasoconstriction to vasodilation [24]. As a con-
sequence, lower expression of ACE2 indicated by a higher degree ofTable 3
Differential methylation of genes invovled in glutamate pathways.
Glutamate signaling
Gene symbol Classiﬁcation β-Diff
CAMK4 Kinases 0.110
GRIA3 AMPA receptor 0.148
GRIN2B NMDA receptor 0.113
GRIK4 GRIK4 0.145
GRM8 Class 3 metabotrope receptor 0.113
SLC1A7 Transporter −0.140
SLC17A7 Transporter 0.125
Glutamate biosynthesis and degradation
GLUD1 Glutamate dehydrogenase 0.183
GLUD2 Glutamate dehydrogenase 0.117
List of genes involved in glutamate signaling (p ≤ 0.05) or glutamate biosynthesis and deg-
radation (p ≤ 0.005) differentially methylated in responders vs nonresponders to RDN and
their classiﬁcation; ß-Diff = methylation (responder)−methylation (nonresponder).methylation would cause the control of BP to be prone to higher BP. In-
terestingly, a reduced expression of ACE2 was found in 3 different
models of hypertension in rats compared to normotensive controls
[25]. Additionally, the genes ADRA1A encoding for the adrenoreceptor
Alpha 1 A, and ADRA2C encoding for the adrenoreceptor Alpha 2C
could indicate a difference in sympathetic signaling between re-
sponders and non-responders. Both genes showed a highermethylation
in the nonresponder group. In sympathetic signaling, the alpha 1 recep-
tors are located on the postsynaptic neuron and bind releasedNE tome-
diate effects on the target tissue, whereas alpha 2 receptors are located
on the presynaptic neuron providingnegative feedback after bindingNE
and inhibiting further NE release [26].
Based on the consideration that other diseases such as cardiac
arrhythmias feature strong sympathetic activity and malfunction of its
self-regulation, researchers and clinicians started to extend application
of RDN to these entities [7–9,27–29]. In a more complex clinical setting,
combination of RDN with pulmonal vein isolation (PVI) in patients suf-
fering from drug resistant hypertension and refractory atrial ﬁbrillation
(AF) showed the expected reduction in BP aswell as signiﬁcantly better
results in reducing AF than in a control group only undergoing PVI [29].
The authors discuss the possibility that this is due to a combination of
reducedmechanical stress caused by lower blood pressure and decrease
of central sympathetic output as a result of reducing afferent renal
nervous sympathetic input [29].
In conclusion, this study provides potential novel mechanisms
underlying non-responsiveness to RDN and, thus, offers potential mo-
lecular targets to further characterize and approach difﬁcult-to-control
and resistant hypertension.
Fig. 3. Pathway analysis deﬁned by software based meta analysis. The graphic depicts molecules involved in glutamate biosynthesis (top) and degradation (bottom); red color indicates
stronger methylation for corresponding genes in responder samples. GLUD 1, 2 = glutamate dehydrogenase 1, 2.
Fig. 4. Differential CpG methylation is associated with reduced norepinephrine levels in
non-responders to RDN. (A) ELISA analysis of EDTA plasma samples. Levels of blood
norepinephrine (NE) were measured in plasma samples by ELISA, n = 5 for responders
and n = 5 for non-responders to RDN, p b 0.05. Error bars show standard error of mean.
(B) Signiﬁcant inverse correlation between levels of plasma NE and BRS-PRSA. Pearson
coefﬁcient r =− 0.70, p b 0.05.
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Our study has limitations such as the low number of patients ana-
lyzed by microarray chip technology. Thus, we cannot exclude a possi-
ble selection bias. All patients were treated with the interventional
device used in the SIMPLICITY trials, and we cannot exclude that a sig-
niﬁcant reduction of blood pressure would have been achieved in the
“non-responder” group using an alternative device. Furthermore, insuf-
ﬁcient attachment of the catheter to the renal artery wall may have
caused non-responsiveness to RDN. Also mechanisms other than sym-
pathetic dependent ones such as factors of the immune system [30]
may be involved in the lack of efﬁcacy of RDN and will have to be eval-
uated in future studies.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ijcha.2016.04.001.Author contributions
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